Antimalarial medication "Lariam". Lariam is fairly expensive at around 3 € per tablet (pricing of the year 2000). A dose of 15–25 mg/kg is recommended, depending on the prevalence of mefloquine resistance. The increased dosage is associated with a much greater level of intolerance, most noticeably in young children; with the drug inducing vomiting and esophagitis. It was not recommended for use during the first trimester, although considered safe during the second and third trimesters; nevertheless, in October 2011, the Centers for Disease Control and Prevention (CDC) changed its recommendation and approved use of Mefloquine for both prophylaxis and treatment of malaria
Treatment of equine lameness cells may be harvested from other horses ahead of time to have banked for immediate treatment of an injury, but there is some concerns of graft-vs-host disease. Stem cells have been used to treat a variety of injuries in horses. The most research has been performed on stem cells used for treatment of tendon and meniscal injuries. Horses with tendonitis treated with bone marrow derived stem cells had a significantly lower re-injury rate compared to those without treatment. Stem cell treatment in damaged tendons is thought to improve the collagen make-up of the tendon while healing. It has been shown